
Results 1 - 20 of 48 in Nexium, Esomeprazole (generic)
FDA Advises Against Use of Clopidogrel With Omeprazole, Other Drugs
The FDA has issued a public health advisory warning consumers to avoid using the stomach acid reducer omeprazole, which is marketed in prescription and OTC formulations as Prilosec, with the anticlotting drug clopidogrel, which is marketed as Plavix. Comment?
FDA: Avoid using Plavix with Prilosec
According to the Food and Drug Administration, patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC with the anti-clotting drug Plavix. Comment?
Effects of esomeprazole treatment for gastroesophageal reflux disease ...
Although gastroesophageal reflux disease is common in adolescents, the burden of GERD on health-related quality of life in adolescents has not been previously evaluated. Comment?
FDA reports significant drug interaction between Prilosec
w/Photo
The FDA has released information from studies showing an important drug interaction between proton pump inhibitors like omeprazole and clopidogrel . Comment?
Heartburn Drugs Reduce Plavix Effectiveness: FDA
The popular heartburn drugs Prilosec and Nexium can reduce by nearly half the blood thinning effect of the drug Plavix, said officials with the U.S. Food and Drug Administration on Tuesday. Comment?
Omeprazole Decreases Effectiveness of Clopidogrel, FDA Says
Patients who are taking clopidogrel should avoid the concomitant use of omeprazole, a proton-pump inhibitor , because the latter drug diminishes the antiplatelet effects of clopidogrel, FDA announced today. Comment?
AstraZeneca sues Lupin for infringing on drug patent
The drug is indicated in case of gastroesophageal reflux disease. The innovator has objected to all the five filings that Lupin has made in its Abbreviated New Drug Application to the US Food and Drug Administration to market the generic version of Nexium with strength 20 and 40 mg. Comment?
The Ports of Indiana, Grantee of Foreign-Trade Zone No. 170, has applied to the Foreign-Trade Zones Board requesting special-purpose foreign-trade subzone status on behalf of Schwarz Pharma Manufacturing Limited. Comment?
GERD Drugs May Cause Unexpected Side Effects
People who are taking drugs called proton pump inhibitors to treat GERD and laryngopharyngeal reflux should be aware of possible unexpected side effects and complications, according to a new report published in Otolaryngologya 'Head and Neck Surgery . Comment?
Third-quarter fiscal 2009 results announced by POZEN
POZEN Inc. , today announced results for the third quarter ended September 30, 2009. Comment?
POZEN Reports Third Quarter 2009 Results
POZEN Inc. , today announced results for the third quarter ended September 30, 2009. Comment?
Patients Taking Vimovo Showed a Decrease in Incidence of NSAID-Associated Ulcers
AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology 2009 Annual Scientific Meeting in Philadelphia, PA. Comment?
Patients Taking VIMOVO(TM) Showed A Decrease In Incidence Of NSAID-Associated Ulcers
Main Category: GastroIntestinal / Gastroenterology Also Included In: Arthritis / Rheumatology ; Conferences ; Clinical Trials / Drug Trials Article Date: 20 Oct 2009 - 1:00 PDT AstraZeneca and POZEN Inc. Comment?
Missed Opportunities in the Trial on Proton-Pump Inhibitor Therapy in Bleeding Peptic Ulcers
We thank all the correspondents for their considered comments. Ms. Yih and Dr. Tejani, Drs. Comment?
AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO
AstraZeneca and POZEN Inc. today announced that they have submitted a Marketing Authorization Application in the European Union via the Decentralised Procedure for VIMOVOa tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis , rheumatoid arthritis and ankylosing spondylitis in patients who are at risk ... Comment?
Medication Can Hasten Bone Loss
Q: I take the acid blocker Nexium and expect that I will need to take it indefinitely. Comment?
Insights into the future of gastric acid suppression
The development of effective acid-suppression therapy has revolutionized the treatment of acid-related diseases. Comment?
Proton pump inhibitor dosing for the healing of erosive esophagitis
The latest issue of the Alimentary Pharmacology & Therapeutics compares standard- with double-dose proton pump inhibitors for the healing of severe erosive esophagitis. Comment?
Pozen Announces FDA Acceptance of NDA For Vimovo
Aug 31, 2009 - POZEN Inc. today announced that the U.S. Food and Drug Administration has accepted the New Drug Application for Vimovo . Comment?
POZEN Announces FDA Acceptance Of NDA For VIMOVO™
Main Category: Arthritis / Rheumatology Also Included In: Regulatory Affairs / Drug Approvals ; Bones / Orthopaedics Article Date: 02 Sep 2009 - 1:00 PDT POZEN Inc. Comment?